Search Results

Stallergenes Greer, a worldwide leader in allergen immunotherapy and Anergis, a leader in ultra-fast AIT research and development, announced the results of a joint research study evaluating the effects of second-generation Contiguous Overlapping Peptides allergen immunotherapy in a therapeutic model of birch pollen allergy, with the aim of shortening AIT administration schemes.

Second-generation Allergen Immunotherapy based on Anergis Contiguous Overlapping Peptides (COP) linked to Virosomes will be tested by Stallergenes Greer using its therapeutic model of birch pollen allergy.

Mymetics Corporation announced that Stallergenes Greer, a worldwide leader in allergen immunotherapy and Anergis, a leader in ultra-fast AIT research and development, reported the results of a joint research study evaluating the effects of the second generation Contiguous Overlapping Peptides allergen immunotherapy in a therapeutic model of birch allergy, with the aim of shortening the AIT administration schemes.